EP1137340A4 - Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände - Google Patents

Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände

Info

Publication number
EP1137340A4
EP1137340A4 EP99965208A EP99965208A EP1137340A4 EP 1137340 A4 EP1137340 A4 EP 1137340A4 EP 99965208 A EP99965208 A EP 99965208A EP 99965208 A EP99965208 A EP 99965208A EP 1137340 A4 EP1137340 A4 EP 1137340A4
Authority
EP
European Patent Office
Prior art keywords
composition
body weight
associated conditions
regulating body
regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99965208A
Other languages
English (en)
French (fr)
Other versions
EP1137340A1 (de
Inventor
Miles B Brennan
Ute Hochgeschwender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Original Assignee
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/374,827 external-priority patent/US6603058B1/en
Application filed by Roosevelt Eleanor Institute for Cancer Research Inc, Oklahoma Medical Research Foundation filed Critical Roosevelt Eleanor Institute for Cancer Research Inc
Publication of EP1137340A1 publication Critical patent/EP1137340A1/de
Publication of EP1137340A4 publication Critical patent/EP1137340A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99965208A 1998-12-09 1999-12-09 Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände Ceased EP1137340A4 (de)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US11158198P 1998-12-09 1998-12-09
US111581P 1998-12-09
US14629999P 1999-07-29 1999-07-29
US14630499P 1999-07-29 1999-07-29
US14630199P 1999-07-29 1999-07-29
US14630699P 1999-07-29 1999-07-29
US14630599P 1999-07-29 1999-07-29
US14630099P 1999-07-29 1999-07-29
US14630399P 1999-07-29 1999-07-29
US14630299P 1999-07-29 1999-07-29
US146300P 1999-07-29
US146301P 1999-07-29
US146304P 1999-07-29
US146303P 1999-07-29
US146306P 1999-07-29
US146305P 1999-07-29
US146299P 1999-07-29
US146302P 1999-07-29
US09/374,827 US6603058B1 (en) 1998-12-09 1999-08-12 Non-human animal model for obesity and uses thereof
PCT/US1999/029337 WO2000033658A1 (en) 1998-12-09 1999-12-09 Composition and method for regulation of body weight and associated conditions
US374827 2003-02-25

Publications (2)

Publication Number Publication Date
EP1137340A1 EP1137340A1 (de) 2001-10-04
EP1137340A4 true EP1137340A4 (de) 2005-12-21

Family

ID=27581011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99965208A Ceased EP1137340A4 (de) 1998-12-09 1999-12-09 Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände

Country Status (6)

Country Link
EP (1) EP1137340A4 (de)
JP (1) JP2003520015A (de)
AU (1) AU3117600A (de)
CA (1) CA2353776A1 (de)
MX (1) MXPA01005818A (de)
WO (1) WO2000033658A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1429073A (zh) * 2000-04-28 2003-07-09 曾根公司 使用α－MSH及其衍生物的基因治疗系统和方法
WO2002006316A2 (en) * 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
EP1322954A4 (de) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst Verfahren zur behandlung von insulinresistenz bei übergewichtigkeit und diabetes
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
FR2857873B1 (fr) * 2003-07-21 2006-02-24 Courtage Et De Diffusion Codif Procede et produit cosmetique destines a limiter la croissance des tissus adipeux
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
KR101176758B1 (ko) * 2004-04-08 2012-08-23 아스테라스 세이야쿠 가부시키가이샤 화합물 ｗｓ727713
US7442693B2 (en) 2004-05-28 2008-10-28 Smithkline Beecham Corporation Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7169773B2 (en) 2004-07-01 2007-01-30 Smithkline Beecham Corporation Compounds
ME01234B (me) * 2004-10-25 2013-06-20 Centocor Inc Mimetička tijela koja vezuju receptore melanokortina, smjese, postupci i upotrebe
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US7790671B2 (en) 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010068A2 (en) * 1996-09-04 1998-03-12 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010068A2 (en) * 1996-09-04 1998-03-12 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"A FRAMESHIFT MUTATION IN HUMAN MC4R IS ASSOCIATED WITH A DOMINANT FORM OF OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 113 - 114, XP000866527, ISSN: 1061-4036 *
"A FRAMESHIFT MUTATION IN MC4R ASSOCIATED WITH DOMINANTLY INHERITED HUMAN OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 111 - 112, XP000866528, ISSN: 1061-4036 *
BANKS W A ET AL: "Permeability of the blood-brain barrier to melanocortins.", PEPTIDES 1995 LNKD- PUBMED:8532602, vol. 16, no. 6, 1995, pages 1157 - 1161, ISSN: 0196-9781 *
BARSH G: "From Agouti to Pomc--100 years of fat blonde mice.", NATURE MEDICINE SEP 1999 LNKD- PUBMED:10470066, vol. 5, no. 9, September 1999 (1999-09-01), pages 984 - 985, ISSN: 1078-8956 *
BERTAGNA XAVIER: "Proopiomelanocortin-derived peptides", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 23, no. 3, 1994, pages 467 - 485, XP009046900, ISSN: 0889-8529 *
BOSTON BRUCE A ET AL: "Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line", ENDOCRINOLOGY, vol. 137, no. 5, 1996, pages 2043 - 2050, XP002326390, ISSN: 0013-7227 *
BRAY G A ET AL: "Medicinal strategies in the treatment of obesity", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 404, 6 April 2000 (2000-04-06), pages 672 - 677, XP002396717, ISSN: 0028-0836 *
CAMPFIEL L A ET AL: "Strategies and Potential Molecular Targets for Obesity Treatment", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 280, 29 May 1998 (1998-05-29), pages 1383 - 1387, XP002977798, ISSN: 0036-8075, DOI: DOI:10.1126/SCIENCE.280.5368.1383 *
CHAGNON YVON C ET AL: "Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study", MOLECULAR MEDICINE (NEW YORK), vol. 3, no. 10, October 1997 (1997-10-01), pages 663 - 673, XP009046979, ISSN: 1076-1551 *
CHEUNG C C ET AL: "PROOPIOMELANOCORTIN NEURONS ARE DIRECT TARGETS FOR LEPTIN IN THE HYPOTHALAMUS", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 138, no. 10, 1997, pages 4489 - 4492, XP009027762, ISSN: 0013-7227 *
FAN W ET AL: "ROLE OF MELANOCORTINERGIC NEURONS IN FEEDING AND THE AGOUTI OBESITY SYNDROME", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 385, 9 January 1997 (1997-01-09), pages 165 - 168, XP002072475, ISSN: 0028-0836 *
FRIEDMAN J M ET AL: "LEPTIN AND THE REGULATION OF BODY WEIGHT IN MAMMALS", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 395, no. 6704, 22 October 1998 (1998-10-22), pages 763 - 770, XP001009891, ISSN: 0028-0836, DOI: DOI:10.1038/27376 *
HUSZAR D ET AL: "TARGETED DISRUPTION OF THE MELANOCORTIN-4 RECEPTOR RESULTS IN OBESITY IN MICE", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 88, no. 1, 10 January 1997 (1997-01-10), pages 131 - 141, XP000877328, ISSN: 0092-8674 *
JACKSON R S ET AL: "Proopiomelanocortin products and human early-onset obesity.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. FEB 1999, vol. 84, no. 2, February 1999 (1999-02-01), pages 819 - 820, XP002326389, ISSN: 0021-972X *
MIZUNO T M ET AL: "HYPOTHALAMIC PRO-OPIOMELANOCORTIN MRNA IS REDUCED BY FASTING IN OB/OB AND DB/DB MICE, BUT IS STIMULATED BY LEPTIN", DIABETES, NEW YORK, NY, US, vol. 47, no. 2, February 1998 (1998-02-01), pages 294 - 297, XP001063909, ISSN: 0012-1797 *
NG T B: "Studies on hormonal regulation of lipolysis and lipogenesis in fat cells of various mammalian species.", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. B, COMPARATIVE BIOCHEMISTRY 1990 LNKD- PUBMED:1962744, vol. 97, no. 3, 1990, pages 441 - 446, ISSN: 0305-0491 *
POGGIOLI R ET AL: "ACTH-(1-24) and alpha-MSH antagonize feeding behaviour stimulated by kappa opiate antagonists", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 7, no. 5, 1986, pages 843 - 848, XP009018115, ISSN: 0196-9781 *
RAMACHANDRAN J ET AL: "Comparison of the steroidogenic and melanotropic activities of corticotropin, alpha-melanotropin and analogs with their lipolytic activities in rat and rabbit adipocytes", BIOCHIMICA ET BIOPHYSICA ACTA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 428, no. 2, 23 April 1976 (1976-04-23), pages 347 - 354, XP025792232, ISSN: 0304-4165, [retrieved on 19760423], DOI: DOI:10.1016/0304-4165(76)90042-8 *
See also references of WO0033658A1 *
YASWEN L ET AL: "Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 5, no. 9, 1 September 1999 (1999-09-01), pages 1066 - 70, XP002190747, ISSN: 1078-8956, DOI: DOI:10.1038/12506 *

Also Published As

Publication number Publication date
MXPA01005818A (es) 2003-07-21
AU3117600A (en) 2000-06-26
CA2353776A1 (en) 2000-06-15
JP2003520015A (ja) 2003-07-02
EP1137340A1 (de) 2001-10-04
WO2000033658A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
EP1137340A4 (de) Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände
DE69820997D1 (de) Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes
DE50012472D1 (de) Verfahren und Vorrichtung zur Spannungsregelung
DE69917037D1 (de) Verfahren zur regeln des haareswachstums
ATE233049T1 (de) Zusammensetzung und verfahren zur kontrolle von schädlichen bio-organismen
DE69725169D1 (de) Zusammensetzungen und verfahren zur anregung des wachstums von neuriten
PL336326A1 (en) Method of and composition for treating sleep apnoea
EP1143987A4 (de) Natürliche zusammensetzung und methode zur behandlung von sexuellen dysfunktionen
DE69943312D1 (de) Manipulator und verfahren zur steuerung seiner lage
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
ZA989875B (en) Composition and method for inhibiting the growth of microorganisms including stabilized sodium hypbromite and isothiazolones
DE69621138D1 (de) Verstellbares federungssystem für sitze und verfahren zur regelung desselben
DE69831358D1 (de) System und verfahren zur vereinfachung des weiterreichens
DE59607774D1 (de) Verfahren zur sensorgesteuerten Bedarfslüftung und Regler zur Durchführung des Verfahrens
DE69602847D1 (de) Tuberkilizide synergistische desinfizierende zusammensetzung und verfahren zur desinfektion
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69926599D1 (de) Verfahren und Vorrichtung zur Reglementierung des Datenverkehrs
DE69810150D1 (de) Motorgeschwindigkeitsregler und verfahren zur einstellung der verstärkung des reglers
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
EP1334118A4 (de) Verfahren und reaktionsmittel zur regulation des zellularen ansprechens in biologischen systemen
HUP0004562A3 (en) Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
HU0001629D0 (en) Method for treating plants and compositions for it
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
DE19881048D2 (de) Anlage und Verfahren zur Regelung des Flüssigkeitshaushaltes von Patienten
EP0928419A4 (de) Zusammensetzungen und verfahren zur regulierung der expression des type-i-interleukin-1-rezeptors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 43/00 B

Ipc: 7A 61P 25/00 B

Ipc: 7A 61P 3/04 B

Ipc: 7A 61K 38/03 B

Ipc: 7A 01K 67/027 B

Ipc: 7G 01N 33/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051107

17Q First examination report despatched

Effective date: 20070403

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110718